Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Launched by TRAVERA INC · Jul 13, 2022

Keywords

ClinConnect Summary

The TraveraRTGx clinical trial is studying a new way to help doctors choose the best treatment for patients with different types of cancer. The trial focuses on looking at tumor cells found in fluids, like pleural effusions (fluid around the lungs) and ascites (fluid in the abdomen), as well as tissue samples from biopsies or surgeries. By analyzing these cells, researchers hope to determine how well patients might respond to specific therapies, which could lead to quicker and more effective treatment decisions.

To participate in this trial, patients must be at least 18 years old and have a diagnosis of any type of carcinoma (a type of cancer). They should also be undergoing treatment that requires a sample of their tumor cells or fluids. Patients will need to provide written consent to join the study and will be asked to participate in a related outcomes registry. If you decide to join, you can expect to help advance cancer research while potentially benefiting from personalized treatment insights based on your tumor's unique response.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient is ≥18 years of age
• • 2. Written Informed Consent provided by patient
• • 3. Diagnosis of any kind of carcinoma
• • 4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
• • 5. Proceeding onto therapy for treatment
• • 6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)
• Exclusion Criteria:
• • 1. Lack of informed consent
• • 2. Unable to obtain sufficient sample